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PROBLEM IDENTIFICATION
 Opiate addiction is a major public health problem nationally and in Bangor, Maine
 Opiate addiction is a chronic disease with a 40-60% relapse rate in patients3
 Several providers at Eastern Maine Medical’s (EMMC) Center for Family Medicine 
(CFM)  prescribe buprenorphine (Subutex) and buprenorphine/naloxone 
(Suboxone) for patients in the greater Bangor area
 CFM provides Suboxone to many patients and is no longer enrolling new patients 
into the program
 With a better understanding of the barriers to recovery, new interventions can be 
used to  better help patients on their road to recovery 
PUBLIC HEALTH COSTS OF OPIOID 
ADDICTION AND TREATMENT IN MAINE 
 Increasing Availability and Decreasing Prices 
 Today in Maine, a single tablet of OxyContin costs $50; 
addicts can find a single-dose packet of heroin for as 
little as $10 6
 Heroin is more available, purity levels are increased, 
street prices have dropped resulting in dramatic increase 
in heroin addiction across the nation 4
 Opiates are Deadly 
 Overdose deaths related to opioid pain relievers has 
increased and exceeds deaths involving heroin and 
cocaine combined in the United States 5
 2014 was the deadliest year in Maine for drug overdoses 
with 208 deaths, a 20% increase from the year before 8
 12.3% of overdose deaths were related to prescription 
opioids in Maine, which is above the national average of 
11.9% 7
 Burden on Crime Enforcement 
 In 2012, heroin accounted for 8 percent of the 
caseload for Maine’s Drug Crimes Task Force; in 2014 
it jumped to 32 percent 6
 Demand on Treatment Facilities 
 Prescription opioids are the second most common 
substance for which treatment is sought, just behind 
alcohol  1
 In 2012 11,518 individuals sought rehab in Maine, of 
these 37.19% primary substance was opiates 2
 Methadone wait lists are 3-4 weeks, Suboxone
treatment even longer 8
 Health Costs 
 Estimated cost of substance abuse in Maine is $1.18 
billion, $888 for each Maine resident 2
 On average opiate abusers generate 8.7 times higher 
direct health costs than non-abusers  5
INTERVENTION AND METHODOLOGY 
 Goal: Develop a descriptive summary of current CFM buprenorphine users to better 
understand barriers to recovery and recommend possible future interventions 
 Methodology
 Retrospective chart review of  patients on buprenorphine who had filled out both the 
Recovery Rating Scale (RRS) and Opiate Craving Scale (n=32) from 7/14/2014 – 7/14/2015
 Summarize demographic data 
 Report average Recovery Rating Scale and Opiate Craving  Scale scores
 Trend patients who have filled out at least 2 Opiate Craving Scale
 Interview community experts and patients about barriers to recovery 
 Intervention 
 Presentation of data to the social workers and buprenorphine providers at EMMC’s CFM
 Share suggestions for program interventions to address barriers to care
 Compile data that can be used in future studies to assess demographics of buprenorphine 
patients 
Patient Demographics
 Sex of Patient (n=32)
 Male = 7 (22%)
 Female= 25 (78%)
 Pregnant = 21 (84%)
 Not pregnant = 4 (16%)
 Average age = 29.56 (n= 32)
 Age at 1st opiate use = 19.48 (n=31)
 Comorbid Mental Health Diagnoses 
(n=32)
 No =  7 (22%)
 Yes = 25 (78%)
 Multiple = 17 (53%)
 Average Adverse Childhood Event Score 
(ACE ) = 5.85 (n=15)
 Previous Recovery Attempts (n=32)
 No = 13 (41%)


























































DATA AND RESULTS Average Recovery Rating Scores
DATA AND RESULTS
Evidence of Program Success
3 patients with completed decreased craving 
scores (starred) 
On average, craving scores for patients on 
medication (blue)
Very high RRS 3 % (orange)
The opiate craving scores reported were on 
average at the 14th visit 











.Average Opiate Craving Scores
Scale Average Max %
RRS 1 23.34 35 67%
RRS 2 27.31 35 78%
RRS 3 18.46 20 92%
OCS 7.72 25 31%















































































 Paula Codrington, LCSW – provides counseling to patients receiving buprenorphine treatment 
at CFM
 Paraphrase: People take a few steps forward and then one back, relapse is part of the recovery 
process so it should be called a challenge not a failure, often people will get stuck and use the idea 
that they failed as the reason to keep using and not keep trying to take steps forward
 Mindset – black and white thinking, the all or nothing perspective makes it more difficult to maintain 
a path towards recovery 
 “If you are not aware of what is going on in your head and heart and your patterns you can’t make 
change, and without being aware of the patterns you can’t get past the hurtles to recovery” 
 Matt Nutt, LCSW – provides counseling to patients receiving buprenorphine treatment at CFM
 Best Guess at whether patients will be successful: the number of life stressors with homelessness, 
lack of healthcare insurance, and unemployment being very important 
 A key to overcoming barriers: “improve access by drastically increasing PCPs willing to treat this 
population, and work to change the stigma associated with working with this population”
COMMUNITY PERSPECTIVE 
 Patient actively receiving Suboxone and counseling at CFM
 What are challenges for you?
 “Other people’s influence.  My neighbor asked me to help her shoot up heroin and it brought 
me right back to the feelings I would have before I used.  The sweats and anxiety…”
 What kind of coping skills have you learned in group therapy that have helped with your 
recovery?
 “Group is good for learning skills to talk about things.  Being around others, having a support 
system is important.  I have learned more to stay away from negative people, like my 
neighbor.  It’s important to change your social situations.” 
 Have you been introduced to mindfulness before? What do you know about it? Do you think it 
would be helpful in the recovery process?
 “I think we got a handout once.  I am not sure what it is…”
 “Doing crafts or coloring which we do sometimes is good to help relieve stress, but it doesn’t 
last.  It’s like a band aid.”
EVALUATION OF EFFECTIVENESS AND 
LIMITATIONS
 Effectiveness 
 This project was successful in identifying 
trends in the demographics of 
buprenorphine patients
 Data was organized in Excel and will be 
distributed to providers and can be added 
to in the future 
 However, there are many additional 
categories of information that could be 
gathered to better understand the 
patient population receiving 
buprenorphine 
 Limitations 
 Only patients who had filled out a 
recovery rating scale and it had been 
scanned into the electronic health record 
between July 2014 and July 2014 were 
reviewed– this is only a small part of the 
patient population
 The Opiate Craving Scale and Recovery 
Rating Scale relies on self reporting –
opiate addicts often have low self esteem 
which could affect reporting 
 The Opiate Craving Scales and Recovery 
Rating Scales were from various stages of 
recovery
 There were differences in the way that 
intake forms were recorded between 
providers which left out information in 
patient’s records
RECOMMENDATIONS FOR THE FUTURE
 There are many more demographic factors not looked at in this study that may contribute 
to success of therapy
 More research could be done to correlate initial recovery scale ratings to recovery success 
as a way to predict success and relapse 
 It was suggested that charts be reviewed to understand the comorbidities of HIV and 
Hepatitis C and how these can be better co-treated in this population
 Standardize use of Opiate Craving Scale at intake of all buprenorphine patients  and at 
specific intervals after the start of treatment to better monitor the changes in cravings 
through the treatment process 
 Continue to maintain treatment as a combination of medications and counseling
 Failure is part of recovery and should be framed as such when discussing the recovery 
process
 Mindfulness practices are a reasonable strategy to introduce into buprenorphine 
treatment as a way to teach healthy coping skills and improve recovery success
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